NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 247 filers reported holding NEKTAR THERAPEUTICS in Q1 2022. The put-call ratio across all filers is 1.00 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $11 | -99.9% | 19,000 | 0.0% | 0.00% | 0.0% |
Q2 2023 | $10,929 | -18.2% | 19,000 | 0.0% | 0.00% | 0.0% |
Q1 2023 | $13,355 | -78.1% | 19,000 | -0.6% | 0.00% | -81.2% |
Q3 2022 | $61,000 | -15.3% | 19,120 | 0.0% | 0.02% | -44.8% |
Q2 2022 | $72,000 | -30.1% | 19,120 | 0.0% | 0.03% | -21.6% |
Q1 2022 | $103,000 | -60.1% | 19,120 | 0.0% | 0.04% | +236.4% |
Q4 2021 | $258,000 | -24.8% | 19,120 | 0.0% | 0.01% | -91.0% |
Q3 2021 | $343,000 | +4.6% | 19,120 | 0.0% | 0.12% | -4.7% |
Q2 2021 | $328,000 | -16.5% | 19,120 | +0.6% | 0.13% | -33.3% |
Q1 2021 | $393,000 | 0.0% | 19,000 | 0.0% | 0.19% | 0.0% |
Q4 2020 | $393,000 | +69.4% | 19,000 | +35.7% | 0.19% | +40.1% |
Q3 2020 | $232,000 | -28.4% | 14,000 | 0.0% | 0.14% | -39.9% |
Q2 2020 | $324,000 | +29.6% | 14,000 | 0.0% | 0.23% | +4.6% |
Q1 2020 | $250,000 | – | 14,000 | – | 0.22% | – |
Q4 2019 | $0 | -100.0% | 0 | -100.0% | 0.00% | -100.0% |
Q3 2019 | $52,000 | +642.9% | 2,870 | +1402.6% | 0.05% | +716.7% |
Q2 2019 | $7,000 | – | 191 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Rhenman & Partners Asset Management AB | 508,000 | $6,132,000 | 1.80% |
Bodri Capital Management, LLC | 250,000 | $3,018,000 | 1.46% |
Granahan Investment Management | 3,442,980 | $41,557,000 | 1.28% |
TIRSCHWELL & LOEWY INC | 603,441 | $7,284,000 | 1.22% |
NEA Management Company, LLC | 1,825,600 | $22,035,000 | 1.12% |
Cormorant Asset Management, LP | 450,000 | $5,432,000 | 1.12% |
HARVEY CAPITAL MANAGEMENT INC | 221,750 | $2,676,000 | 1.05% |
Cheyne Capital Management (UK) LLP | 229,577 | $2,772,000 | 0.99% |
Artal Group S.A. | 1,650,000 | $19,916,000 | 0.73% |
FIC CAPITAL INC | 147,293 | $1,778,000 | 0.71% |